The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease

被引:16
|
作者
Drexel, Heinz [2 ,3 ,4 ,5 ]
Larcher, Barbara [1 ,2 ,3 ]
Mader, Arthur [1 ,2 ,3 ]
Vonbank, Alexander [1 ,2 ,3 ]
Heinzle, Christine F. [2 ]
Moser, Berthold [6 ,7 ]
Zanolin-Purin, Daniela [2 ,3 ]
Saely, Christoph H. [1 ,2 ,3 ]
机构
[1] Acad Teaching Hosp Feldkirch, Dept Med 1, Carinagasse 47, A-6800 Feldkirch, Austria
[2] Vorarlberg Inst Vasc Invest & Treatment VIVIT, Carinagasse 47, A-6800 Feldkirch, Austria
[3] Private Univ Principal Liechtenstein, Dorfstr 24, FL-9495 Triesen, Liechtenstein
[4] Landeskrankenhaus Bregenz, Dept Internal Med, Carl Pedenz Str 2, A-6900 Bregenz, Austria
[5] Drexel Univ, Coll Med, 2900W Queen Lane, Philadelphia, PA 19129 USA
[6] See Spital Horgen, Dept Anaesthesia, Asylstr 19, CH-8810 Horgen, Switzerland
[7] Med Univ Innsbruck, Dept Anaesthesiol & Intens Care Med, Anichstr 35, A-6020 Innsbruck, Austria
关键词
LDL-C; ApoB ratio; LDL particle size; Prospective cohort study; Major cardiovascular events; Lipids; Risk prediction; Atherosclerosis; PERIPHERAL ARTERY-DISEASE; LIPOPROTEIN SUBFRACTIONS; REVERSE EPIDEMIOLOGY; METABOLIC SYNDROME; RISK-FACTORS; ASSOCIATION; CHOLESTEROL; GUIDELINES; MANAGEMENT; PARTICLES;
D O I
10.1016/j.atherosclerosis.2021.05.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: The low density lipoprotein cholesterol to Apolipoprotein B (LDL-C/ApoB) ratio is a validated proxy for low density lipoprotein (LDL) particle size that can be easily calculated from a standard lipid/ apolipoprotein profile. Whether it is predictive of cardiovascular events in patients with established atherosclerosis is not known and is addressed in the present investigation. Methods: We determined the LDL-C/ApoB ratio in a cohort of 1687 subjects with established atherosclerosis. Prospectively, major cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke were recorded over a period of 9.9 +/- 4.6 years. The study covers >16,000 patient years. Results: At baseline, the LDL-C/ApoB ratio was 1.36 +/- 0.28 in our cohort. During follow up, a total of 558 first MACE were recorded. The LDL-C/ApoB ratio predicted MACE in univariate Cox proportional hazard analysis (HR 0.90 [0.82-0.98]; p = 0.014); this finding was confirmed after adjustment for age, gender, intensity of statin treatment, hypertension, history of smoking, type 2 diabetes, body mass index and ApoB (HR 0.87 [0.78-0.97]; p = 0.013). Conclusions: The LDL-C/ApoB ratio is independently predictive of MACE in subjects with established atherosclerosis.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 50 条
  • [21] Remnant cholesterol predicts major cardiovascular events in cardiovascular disease patients with NAFLD
    Larcher, B.
    Mader, A.
    Sprenger, L.
    Vonbank, A.
    Maechler, M.
    Plattner, T.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    Saely, C. H.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [22] Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors
    Miao, Benjamin
    Hernandez, Adrian V.
    Alberts, Mark J.
    Mangiafico, Nicholas
    Roman, Yuani M.
    Coleman, Craig I.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (02):
  • [23] Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease
    Berman, Adam N.
    Biery, David W.
    Besser, Stephanie A.
    Singh, Avinainder
    Shiyovich, Arthur
    Weber, Brittany N.
    Huck, Daniel M.
    Divakaran, Sanjay
    Hainer, Jon
    Kaur, Gurleen
    Blaha, Michael J.
    Cannon, Christopher P.
    Plutzky, Jorge
    Januzzi, James L.
    Booth, John N.
    Lopez, J. Antonio G.
    Kent, Shia T.
    Nasir, Khurram
    Carli, Marcelo F. Di
    Bhatt, Deepak L.
    Blankstein, Ron
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (09) : 873 - 886
  • [24] Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study
    Erin S. Mackinnon
    Lawrence A. Leiter
    Rajvi J. Wani
    Natasha Burke
    Eileen Shaw
    Kelcie Witges
    Shaun G. Goodman
    [J]. Cardiology and Therapy, 2024, 13 : 205 - 220
  • [25] Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study
    Mackinnon, Erin S.
    Leiter, Lawrence A.
    Wani, Rajvi J.
    Burke, Natasha
    Shaw, Eileen
    Witges, Kelcie
    Goodman, Shaun G.
    [J]. CARDIOLOGY AND THERAPY, 2024, 13 (01) : 205 - 220
  • [26] Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels
    Maury, Eleonore
    Brouyere, Samuel
    Jansen, Mieke
    [J]. CLINICAL CARDIOLOGY, 2024, 47 (09)
  • [27] Type 2 Diabetes, Chronic Kidney Disease, and Major Cardiovascular Events in Patients With Established Cardiovascular Disease
    Sprenger, Lukas
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    [J]. CIRCULATION, 2022, 146
  • [28] TYPE 2 DIABETES, CHRONIC KIDNEY DISEASE AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE
    Sprenger, L.
    Maechler, M.
    Vonbank, A.
    Larcher, B.
    Mader, A.
    Plattner, T.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    Saely, C.
    [J]. ATHEROSCLEROSIS, 2023, 379
  • [29] Type 2 Diabetes, Chronic Kidney Disease, and Major Cardiovascular Events in Patients with Established Cardiovascular Disease
    Sprenger, Lukas
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    [J]. DIABETES, 2022, 71
  • [30] Type 2 diabetes, chronic kidney disease and major cardiovascular events In patients with established cardiovascular disease
    Sprenger, L.
    Maechler, M.
    Vonbank, A.
    Larcher, B.
    Mader, A.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    Saely, C. H.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 2) : 170 - 171